ReviewBiomedicines2024
Prediabetes and Cardiometabolic Risk: The Need for Improved Diagnostic Strategies and Treatment to Prevent Diabetes and Cardiovascular Disease.
Review in Biomedicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effects of probiotic supplementation on islet β-cell function in subjects with glucose metabolism disorders: a meta-analysis.Frontiers in nutrition · 2025Pooled it
- Growth differentiation factor-15 and body roundness index in relation to cardiometabolic risk in young adults with obesity.Endocrine · 2026Article
- Cardiovascular-Kidney-Metabolic Syndrome and Its Hepatic Dimension: A Narrative Review.Medicina (Kaunas, Lithuania) · 2026Review
- Stratification of Pro-Atherogenic Phenotypes in Prediabetes Using Machine Learning.Biomedicines · 2026Article
- One-hour postload glucose compared to prediabetes criteria as predictive markers of type 2 diabetes in Latin America.Journal of the Endocrine Society · 2026Article
- The transition from preclinical to clinical obesity: the importance of a borderline stage.Clinical science (London, England : 1979) · 2026Review
- Postprandial 2-h glucose tolerance is associated with diabetes diagnosis, diabetes mortality, and cardiovascular mortality.Scientific reports · 2025Article
- Prediabetes and atrial fibrillation risk stratification, phenotyping, and possible reversal to normoglycemia.World journal of diabetes · 2025Article
- The Silent Threat: A Retrospective Cohort Study on the Impact of Prediabetes on ST-Elevation Myocardial Infarction Survival-A Call to Action!Biomedicines · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The progression from prediabetes to type-2 diabetes depends on multiple pathophysiological, clinical, and epidemiological factors that generally overlap. Both insulin resistance and decreased insulin secretion are considered to be the main causes. The diagnosis and approach to the prediabetic patient are heterogeneous. There is no agreement on the diagnostic criteria to identify prediabetic subjects or the approach to those with insufficient responses to treatment, with respect to regression to normal glycemic values or the prevention of complications. The stratification of prediabetic patients, considering the indicators of impaired fasting glucose, impaired glucose tolerance, or HbA1c, can help to identify the sub-phenotypes of subjects at risk for T2DM. However, considering other associated risk factors, such as impaired lipid profiles, or risk scores, such as the Finnish Diabetes Risk Score, may improve classification. Nevertheless, we still do not have enough information regarding cardiovascular risk reduction. The sub-phenotyping of subjects with prediabetes may provide an opportunity to improve the screening and management of cardiometabolic risk in subjects with prediabetes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.